Literature DB >> 10131467

Introducing new cost effective treatments into the NHS. Surfactant treatment for premature babies: who cares enough to pay?

H L Halliday1.   

Abstract

Mesh：

Substances：

Year:  1993        PMID： 10131467      PMCID： PMC1055129          DOI： 10.1136/qshc.2.3.195

Source DB:  PubMed          Journal:  Qual Health Care        ISSN： 0963-8172


× No keyword cloud information.
  13 in total

1.  Estimated costs of different treatments of the respiratory distress syndrome in a large cohort of preterm infants of less than 30 weeks of gestation.

Authors:  J Egberts
Journal:  Biol Neonate       Date:  1992

2.  Surface properties in relation to atelectasis and hyaline membrane disease.

Authors:  M E AVERY; J MEAD
Journal:  AMA J Dis Child       Date:  1959-05

3.  Putting the clock back 30 years: neonatal care since the 1991 NHS reforms.

Authors:  C Pope; D Wild
Journal:  Arch Dis Child       Date:  1992-07       Impact factor: 3.791

4.  Cost of surfactant replacement treatment for severe neonatal respiratory distress syndrome: a randomised controlled trial.

Authors:  T R Tubman; H L Halliday; C Normand
Journal:  BMJ       Date:  1990-10-13

5.  Surfactant replacement therapy: impact on hospital charges for premature infants with respiratory distress syndrome.

Authors:  W M Maniscalco; J W Kendig; D L Shapiro
Journal:  Pediatrics       Date:  1989-01       Impact factor: 7.124

6.  The effects of corticosteroid administration before preterm delivery: an overview of the evidence from controlled trials.

Authors:  P Crowley; I Chalmers; M J Keirse
Journal:  Br J Obstet Gynaecol       Date:  1990-01

7.  A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants.

Authors:  G C Liggins; R N Howie
Journal:  Pediatrics       Date:  1972-10       Impact factor: 7.124

8.  Artificial surfactant therapy in hyaline-membrane disease.

Authors:  T Fujiwara; H Maeta; S Chida; T Morita; Y Watabe; T Abe
Journal:  Lancet       Date:  1980-01-12       Impact factor: 79.321

9.  Impact of antenatal dexamethasone administration on respiratory distress syndrome in surfactant-treated infants.

Authors:  E E Farrell; R K Silver; L V Kimberlin; E S Wolf; J M Dusik
Journal:  Am J Obstet Gynecol       Date:  1989-09       Impact factor: 8.661

10.  Growth in prescription medicines expenditure: a European comparison.

Authors:  J P Griffin; R B Chew
Journal:  J R Coll Physicians Lond       Date:  1993-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.